NCT07626476

Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

RecruitingEARLY_PHASE1INTERVENTIONAL

Trial Details

Start: 2024-12-16Est. Completion: 2027-12-15

Enrollment target: 30 participants

Locations

Contact

Recurrent AL AmyloidosisRefractory AL Amyloidosis

This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and …

Duarte, United StatesEst. completion Jun 30, 2028

Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for…

Duarte, United StatesEst. completion Apr 19, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.